Bone and Cancer
Bone and Cancer
Bone and CancerBone and Cancer Foundation, PO Box 287452 Bone and Cancer New York, NY 10128-0025  
Toll Free: 888 862-0999 Bone and Cancer Email: bcfdn@aol.com  
Bone and Cancer

Clinical Trials

Vancenase AQ 84 mcg Double Strength

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company:

Approval Status:

Approved June 1996

Specific Treatments:

allergic and non-allergic rhinitis

General Information

Vancenase AQ 84 mcg Double Strength, a once-daily aqueous corticosteroid nasal spray for adults and children six years of age and over, has been approved by the FDA.

Available by prescription, Vancenase AQ 84 mcg Double Strength is indicated for the relief of symptoms of allergic and non-allergic (vasomotor) rhinitis, including sneezing, runny nose, and nasal congestion. Vancenase AQ 84 mcg Double Strength is a concentrated form of Vancenase AQ, a twice-daily formulation. The new Vancenase AQ formulation delivers 84 mcg of beclomethasone dipropionate per dose (two metered sprays, once daily), twice the amount of medication released in the same dosage of Vancenase AQ.

Clinical Results

Clinical trials with Vancenase AQ 84 mcg Double Strength in subjects with seasonal allergic rhinitis showed that this concentrated, once-daily medication is as safe and effective in relieving the symptoms of allergic rhinitis as the original formulation. In a recent study of 194 subjects diagnosed with allergic rhinitis, Vancenase AQ 84 mcg Double Strength, administered once daily, significantly reduced nasal symptoms when compared with placebo. The incidence of side effects in subjects treated with Vancenase AQ 84 mcg Double Strength was similar to that found with placebo.

 How To Order Publications:
  Glossary
  FAQ

Information About

Clinical Trials



 

 

 

 

 

 

 

 

 

 

 


 

 

 

 

 

 

 


  Copyright 2011 - The Bone and Cancer Foundation